ROIV (ROIV) insider Mayukh Sukhatme plans $9M Rule 144 stock sale

Rhea-AI Filing Summary

Roivant Sciences (ROIV) insider plans new share sale under Rule 144. A holder intends to sell 339,441 common shares through Rockefeller Financial LLC on NASDAQ, with an aggregate market value of 8,985,275.71. The issuer reports 715,701,137 shares outstanding.

The shares to be sold were acquired on 02/09/2026 via an options grant originally dated 03/26/2020, with payment made by wire. Over the prior three months, Mayukh Sukhatme sold additional ROIV shares in three transactions totaling 1,307,699 shares, for combined gross proceeds of about 29.0M.

Insights

Equity capital markets analyst

Medium-sized insider Rule 144 sales, routine but notable in scale.

The notice shows a planned sale of 339,441 ROIV common shares on NASDAQ, with aggregate market value of 8,985,275.71. These shares stem from an options grant dated 03/26/2020 and were acquired on 02/09/2026 with payment by wire.

In the prior three months, Mayukh Sukhatme completed three additional ROIV sales: 1,018,995 shares for 22,119,828.43 on 12/31/2025, 311,873 shares for 6,781,263.07 on 12/29/2025, and 26,831 shares for 619,487.59 on 12/17/2025. Together these represent meaningful personal liquidity but occur against a base of 715,701,137 shares outstanding.

The filing includes the standard representation that the seller does not know any undisclosed material adverse information about the issuer’s current or prospective operations. Actual market impact, if any, will depend on execution of the planned sale and broader trading conditions at the time.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Rockefeller Financial LLC 45 Rockefeller Plaza Floor 5 New York NY 10111	339441	8985275.71	715701137	02/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/09/2026	Options Grant - 3/26/2020	ROIV			339441	02/09/2026	wire

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mayukh Sukhatme 7th Floor - 50 Broadway London X0 SW1H 0BL	ROIV	12/31/2025	1018995	22119828.43
Mayukh Sukhatme 7th Floor - 50 Broadway London X0 SW1H0BL	ROIV	12/29/2025	311873	6781263.07
Mayukh Sukhatme 7th Floor - 50 Broadway London X0 SW1H0BL	ROIV	12/17/2025	26831	619487.59

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ROIV Rule 144 filing disclose about upcoming share sales?

The filing discloses a planned sale of 339,441 ROIV common shares on NASDAQ, with aggregate market value of about 8,985,275.71. These shares were recently acquired via an options grant and will be sold for the account of the listed holder through Rockefeller Financial LLC.

How many Roivant Sciences (ROIV) shares are outstanding in this filing?

The notice reports 715,701,137 ROIV common shares outstanding. This figure provides context for the planned Rule 144 sale of 339,441 shares, helping investors gauge the relative size of the transaction compared with the company’s total share base at that time.

Who is selling ROIV shares and through which broker under this Rule 144 notice?

The Rule 144 notice covers sales for the account of Mayukh Sukhatme, with Rockefeller Financial LLC listed as the broker. The planned transaction involves 339,441 common shares of ROIV to be sold on NASDAQ, subject to Rule 144 conditions and normal market execution.

What prior ROIV share sales by Mayukh Sukhatme are disclosed in the last three months?

The filing lists three prior ROIV sales: 1,018,995 shares for 22,119,828.43 on 12/31/2025, 311,873 shares for 6,781,263.07 on 12/29/2025, and 26,831 shares for 619,487.59 on 12/17/2025, all reported as gross proceeds.

How were the ROIV shares in the new Rule 144 sale acquired?

The 339,441 ROIV common shares to be sold were acquired on 02/09/2026 through an options grant originally dated 03/26/2020. The filing notes the acquisition used a wire transfer for payment, indicating a cash settlement for exercising the options.

What representation does the ROIV seller make regarding undisclosed information?

The seller represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed. This is a standard certification included in Rule 144 notices relating to the planned sale of restricted or control securities.